Content » Vol 41, Issue 7

Short communication

Safety of methylphenidate following traumatic brain injury: Impact on vital signs and side-effects during inpatient rehabilitation

Catherine Willmott, Jennie Ponsford, John Olver, Michael Ponsford
DOI: 10.2340/16501977-0369

Abstract

Objective: The aim of the present study was to evaluate the safety of methylphenidate administered during inpatient rehabilitation following traumatic brain injury.
Methods: Forty inpatients with moderate-severe traumatic brain injury (mean 68.4 days post-injury) participated in a randomized, cross-over, double-blind, placebo-controlled trial of methylphenidate administered at a dose of 0.3 mg/kg body weight twice daily.
Results: Methylphenidate administration resulted in a statistically significant increase in pulse of 12.3 beats/min (95% confidence interval (CI) 9.25–15.36), diastolic blood pressure of 4.1 mmHg (95% CI 2.11–6.10), and mean arterial pressure of 3.75 mmHg (95% CI 1.79–5.72). These changes did not, however, appear to be symptomatic, as no participants were withdrawn due to adverse events, and there was no significant self-report of increased heart rate with methylphenidate. Blinding was successful. Significantly greater reporting of irritability of 0.14 points (95% CI 0.02–0.26), difficulty sleeping of 0.17 points (95% CI 0.02–0.31) and total side-effects of 0.68 points (95% CI 0.06–1.30) was associated with methylphenidate compared with placebo.
Conclusion: Methylphenidate given at 0.3 mg/kg body weight appears to be safe in the inpatient rehabilitation phase. This trial is registered with the Australian New Zealand Clinical Trials Registry (12607000503426).

Lay Abstract

Comments

Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors. You need to login/create an account to comment on articles. Click here to login/create an account.
Advertisement